Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 4/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | GAPDH | P04406 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17871148 | 0.90 | HDAC1 (0.38) | CA2CA1CTSKGRIK1GRIK2 | |
| SCHEMBL27695836 | 0.85 | TSHR (0.42) | CA2CA1ZDHHC7CTSKGRIK1 | |
| SCHEMBL28664768 | 0.84 | CA2 (0.50) | CA2CA1ZDHHC7GRIK1GRIK2 | |
| SCHEMBL7367485 | 0.84 | CA2 (0.50) | CA2CA1ZDHHC7GRIK1GRIK2 | |
| SCHEMBL28380817 | 0.84 | CA2 (0.50) | CA2CA1ZDHHC7GRIK1GRIK2 | |
| SCHEMBL24360474 | 0.84 | CA2 (0.50) | CA2CA1ZDHHC7CTSKGRIK1 | |
| SCHEMBL18597124 | 0.84 | CA2 (0.50) | CA2CA1ZDHHC7GRIK1GRIK2 | |
| SCHEMBL18597120 | 0.84 | CA2 (0.50) | CA2CA1ZDHHC7GRIK1GRIK2 | |
| SCHEMBL22880855 | 0.84 | CA2 (0.50) | CA2CA1ZDHHC7GRIK1GRIK2 | |
| SCHEMBL28381502 | 0.84 | CA2 (0.50) | CA2CA1ZDHHC7GRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191406-A1 | Heterocyclic antiviral compounds | CCR5, CX3CR1, CXCR1 | CA2 4464/4885CA1 4663/4885ZDHHC7 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.